COSCIENS Biopharma Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update

Fully repositioned as a pure-play natural-based product company following strategic review and pipeline prioritization

Ongoing streamlined efficiencies and cost cutting measures taken to refine operations and development pathway forward; Company ended the quarter with US$16.4 million in cash

Read more at globenewswire.com